EUCTR2005-004056-13-HU进行中（未招募）不适用
A phase III, multicentric, multinational, long-term follow-up study to evaluate the persistence of anti-HBs antibodies at Months 12, 24 and 36 in pre-dialysis / peritoneal dialysis or haemodialysis patients who had previously received a primary vaccination course of either Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V or GlaxoSmithKline Biologicals’ Fendrix - HN015/HBVEXT001
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Henogen
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·Subjects for whom the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol (e.g., return for follow-up visits) should be enrolled in the study.
- •·Written informed consent obtained from the subject/ from the parent/ guardian of the subject at the first long-term time point that the subject comes back to participate in this study.
- •·Subjects who completed the full course of primary vaccination (three doses of HBV-AS02V vaccine or four doses of Fendrix vaccine) in the study 105757 (HN014/HBV-001) and return at any of the long-term time points (i.e. 12, 24 or 36 months) after the first dose of the primary vaccination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Immunosuppression caused by the administration of parenteral steroids or chemotherapy.
- •·Any confirmed or suspected human immunodeficiency virus (HIV) infection.
研究者
相似试验
进行中（未招募）
不适用
A phase III, multicentric, multinational, long-term follow-up study to evaluate the persistence of anti-HBs antibodies at Months 12, 24 and 36 in pre-dialysis / peritoneal dialysis or haemodialysis patients who had previously received a primary vaccination course of either Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V or GlaxoSmithKline Biologicals’ Fendrix - HN015/HBVEXT001hepatitis B pre-dialysis, peritoneal dialysis and haemodialysis patient from 15 year of ageEUCTR2005-004056-13-CZHenogen300
进行中（未招募）
1 期
A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, administered according to 0, 1, 6 months schedule to that of GlaxoSmithKline Biologicals’ adjuvanted hepatitis B vaccine, Fendrix®, administered according to 0, 1, 2, 6 months schedule, in hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients (above or equal to 15 years of age). - HN014/HBV-001hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients from 15 years of ageEUCTR2005-004053-10-CZHenogen300
进行中（未招募）
不适用
A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, administered according to 0, 1, 6 months schedule to that of GlaxoSmithKline Biologicals’ adjuvanted hepatitis B vaccine, Fendrix®, administered according to 0, 1, 2, 6 months schedule, in hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients (above or equal to 15 years of age). - HN014/HBV-001hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients from 15 years of ageEUCTR2005-004053-10-BEHenogen300
进行中（未招募）
不适用
A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to that of Aventis Pasteur MSD’s hepatitis B vaccine, HBVAXPRO® , administered as a booster dose in pre-dialysis, peritoneal dialysis and haemodialysis subjects (above or equal to 15 years of age) who previously responded to hepatitis B primary vaccination but have lost antibody. - HN018/HBV-004EUCTR2005-004059-37-CZHenogen120
进行中（未招募）
不适用
A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, administered according to 0, 1, 6 months schedule to that of GlaxoSmithKline Biologicals’ adjuvanted hepatitis B vaccine, Fendrix®, administered according to 0, 1, 2, 6 months schedule, in hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients (above or equal to 15 years of age). - HN014/HBV-001hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients from 15 years of ageEUCTR2005-004053-10-HUHenogen300